<DOC>
	<DOCNO>NCT02662452</DOCNO>
	<brief_summary>The purpose First-in-Human study evaluate safety tolerability single ascend oral dos GLPG2222 give healthy subject , compare placebo ( Part 1 ) . Also , safety tolerability multiple ascend oral dos GLPG2222 give healthy subject daily 14 day compare placebo , evaluate ( Part 2 ) . Furthermore , course study single multiple oral dose administration , amount GLPG2222 present blood urine ( pharmacokinetics ) characterize . The potential cytochrome P450 ( CYP ) 3A4 interaction repeat dose GLPG2222 explore well .</brief_summary>
	<brief_title>First-in-Human Single Multiple Dose GLPG2222</brief_title>
	<detailed_description />
	<criteria>Males 1850 year age Subjects must body mass index 1830 kg/m² Subjects must judge good health base upon result medical history , physical examination , vital sign , 12lead electrocardiogram laboratory profile Subjects must screen spirometry force expiratory volume 1 second ≥80 % predict value age , gender height ( Part 1 ) A subject know hypersensitivity study drug ingredient significant allergic reaction drug Concurrent participation participation within 8 week prior initial study drug administration drug/device biologic investigational research study A subject active drug alcohol abuse within 2 year prior initial study drug administration Current sexually active ( and/or child wish ) male ; contraception method must use</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>